ASH 2021 – Alessandra Tedeschi
Alessandra Tedeschi depicts her personal highlights reported at ASH 2021 and explains the results obtained in treatment-naïve CLL patients with a deletion of 17p in the SEQUOIA study. The influence of age, fitness, and concomitant medications on the management and outcomes of patients with CLL treated with targeted agents, the most notable progress in B-cell malignancies over the last years and the role of BTK inhibitors in the treatment of patients with Waldenström’s macroglobulinemia are summarized, too.
Here is the full ASH 2021 report.
More posts
Promising novel approaches in various B-cell malignancies
Promising novel approaches in various B-cell malignancies POLARIX: polatuzumab
Phase II data on novel BTK inhibitors for patients with Waldenström’s macroglobulinemia
Phase II data on novel BTK inhibitors for patients with Waldenström’s macroglobulin
Marginal zone lymphoma: PI3Kδ inhibition and beyond
Marginal zone lymphoma: PI3Kδ inhibition and beyond CITADEL-204: parsaclisib in
Mantle cell lymphoma: refining clinical outcomes beyond the current boundaries
Mantle cell lymphoma: refining clinical outcomes beyond the current boundaries
Management of patients with relapsed/refractory CLL: what is new?
Management of patients with relapsed/refractory CLL: what is new? VISION: stop-
Determining first-line CLL/SLL treatment strategies with optimized efficacy and safety
Determining first-line CLL/SLL treatment strategies with optimized efficacy and saf
